Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility

Nature Genetics

Volumn 49, Issue 3, 2017, Pages 438-443

  Takeuchi, Masaki ^a,b   Mizuki, Nobuhisa ^b   Meguro, Akira ^b   Ombrello, Michael J ^c   Kirino, Yohei ^b   Satorius, Colleen ^a   Le, Julie ^a   Blake, Mary ^c   Erer, Burak ^a   Kawagoe, Tatsukata ^b   Ustek, Duran ^d   Tugal Tutkun, Ilknur ^e   Seyahi, Emire ^e   Ozyazgan, Yilmaz ^e   Sousa, Inês ^f,g   Davatchi, Fereydoun ^h   Francisco, Vânia ^f,g   Shahram, Farhad ^h   Abdollahi, Bahar Sadeghi ^h   Nadji, Abdolhadi ^h   Shafiee, Niloofar Mojarad ^h   Ghaderibarmi, Fahmida ^h   Ohno, Shigeaki ⁱ   Ueda, Atsuhisa ^b   Ishigatsubo, Yoshiaki ^b   Gadina, Massimo ^c   Oliveira, Sofia A ^f,g   Gül, Ahmet ^e   Kastner, Daniel L ^a   Remmers, Elaine F ^a   more..

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^d ISTANBUL UNIVERSITY   (Turkey)

^e ISTANBUL UNIVERSITY   (Turkey)

^f INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^g INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^h TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁱ HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADO PROTEIN; CCAAT ENHANCER BINDING PROTEIN BETA; EARLY GROWTH RESPONSE FACTOR 2; ERAP1 PROTEIN; FUT2 PROTEIN; HLA B ANTIGEN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 1A; INTERLEUKIN 1ALPHA; INTERLEUKIN 1B; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 23 RECEPTOR; KLRC4 PROTEIN; LACC1 PROTEIN; PROTEIN; PROTEIN TYROSINE PHOSPHATASE 1B; RIPK2 PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BACTERIUM; BEHCET DISEASE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENE LOCUS; GENE REPLICATION; GENETIC IDENTIFICATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; GENOTYPE; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LEPROSY; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; CASE CONTROL STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; IRAN; MALE; PROCEDURES;

ADULT; ALLELES; BEHCET SYNDROME; CASE-CONTROL STUDIES; FEMALE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; IRAN; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; TURKEY;

EID: 85011715812     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3786     Document Type: Article

References (58)

1. Sakane, T., Takeno, M., Suzuki, N. & Inaba, G. Behçet's disease. N. Engl. J. Med. 341, 1284-1291 (1999).
2. Hatemi, G. et al. EULAR recommendations for the management of Behçet disease. Ann. Rheum. Dis. 67, 1656-1662 (2008).
3. Verity, D.H., Marr, J.E., Ohno, S., Wallace, G.R. & Stanford, M.R. Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54, 213-220 (1999).
4. Gul, A. & Ohno, S. HLA-B∗51 and Behçet disease. Ocul. Immunol. Inflamm. 20, 37-43 (2012).
5. Ono, S., Aoki, K., Sugiura, S., Nakayama, E. & Itakura, K. HL-A5 and Behçet's disease. Lancet 2, 1383-1384 (1973).
6. de Menthon, M., Lavalley, M.P., Maldini, C., Guillevin, L. & Mahr, A. HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 61, 1287-1296 (2009).
7. Remmers, E.F. et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat. Genet. 42, 698-702 (2010).
8. Mizuki, N. et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat. Genet. 42, 703-706 (2010).
9. Kirino, Y. et al. Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B∗51 and ERAP1. Nat. Genet. 45, 202-207 (2013).
10. Li, H. et al. TNFAIP3 gene polymorphisms confer risk for Behçet's disease in a Chinese Han population. Hum. Genet. 132, 293-300 (2013).
11. Kirino, Y. et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behçet disease. Proc. Natl. Acad. Sci. USA 110, 8134-8139 (2013).
12. Xavier, J.M. et al. FUT2: filling the gap between genes and environment in Behçet's disease? Ann. Rheum. Dis. 74, 618-624 (2015).
13. Kappen, J.H. et al. Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Behçet disease. PLoS One 10, e0119085 (2015).
14. Ortiz-Fernández, L. et al. Genetic analysis with the Immunochip platform in Behçet disease. Identification of residues associated in the HLA class I region and new susceptibility loci. PLoS One 11, e0161305 (2016).
15. Cortes, A. & Brown, M.A. Promise and pitfalls of the Immunochip. Arthritis Res. Ther. 13, 101 (2011).
16. Ombrello, M.J. et al. Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. USA 111, 8867-8872 (2014).
17. Hughes, T. et al. Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease. Nat. Genet. 45, 319-324 (2013).
18. Barland, C.O. et al. Imiquimod-induced interleukin-1α stimulation improves barrier homeostasis in aged murine epidermis. J. Invest. Dermatol. 122, 330-336 (2004).
19. Vonk, A.G. et al. Endogenous interleukin (IL)-1α and IL-1β are crucial for host defense against disseminated candidiasis. J. Infect. Dis. 193, 1419-1426 (2006).
20. Liang, L. et al. IL-1β triggered by peptidoglycan and lipopolysaccharide through TLR2/4 and ROS-NLRP3 inflammasome-dependent pathways is involved in ocular Behçet's disease. Invest. Ophthalmol. Vis. Sci. 54, 402-414 (2013).
21. Kim, E.H., Park, M.J., Park, S. & Lee, E.S. Increased expression of the NLRP3 inflammasome components in patients with Behçet's disease. J. Inflamm. (Lond.) 12, 41 (2015).
22. Caso, F. et al. Biological treatments in Behçet's disease: beyond anti-TNF therapy. Mediators Inflamm. 2014, 107421 (2014).
23. Gül, A. et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Ann. Rheum. Dis. 71, 563-566 (2012).
24. Ferrer-Admetlla, A. et al. A natural history of FUT2 polymorphism in humans. Mol. Biol. Evol. 26, 1993-2003 (2009).
25. Franke, A. et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42, 1118-1125 (2010).
26. Hu, D.Y. et al. Associations of FUT2 and FUT3 gene polymorphisms with Crohn's disease in Chinese patients. J. Gastroenterol. Hepatol. 29, 1778-1785 (2014).
27. Wacklin, P. et al. Secretor genotype (FUT2 gene) is strongly associated with the composition of Bifidobacteria in the human intestine. PLoS One 6, e20113 (2011).
28. Rausch, P. et al. Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotype. Proc. Natl. Acad. Sci. USA 108, 19030-19035 (2011).
29. Sheinfeld, J., Schaeffer, A.J., Cordon-Cardo, C., Rogatko, A. & Fair, W.R. Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. N. Engl. J. Med. 320, 773-777 (1989).
30. Marionneau, S., Airaud, F., Bovin, N.V., Le Pendu, J. & Ruvoën-Clouet, N. Influence of the combined ABO, FUT2, and FUT3 polymorphism on susceptibility to Norwalk virus attachment. J. Infect. Dis. 192, 1071-1077 (2005).
31. Rupp, C. et al. Fut2 genotype is a risk factor for dominant stenosis and biliary candida infections in primary sclerosing cholangitis. Aliment. Pharmacol. Ther. 39, 873-882 (2014).
32. Hatemi, I. et al. Frequency of pathergy phenomenon and other features of Behçet's syndrome among patients with inflammatory bowel disease. Clin. Exp. Rheumatol. 26 (Suppl. 50), S91-S95 (2008).
33. Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119-124 (2012).
34. Zhang, F.R. et al. Genomewide association study of leprosy. N. Engl. J. Med. 361, 2609-2618 (2009).
35. Liu, H. et al. Discovery of six new susceptibility loci and analysis of pleiotropic effects in leprosy. Nat. Genet. 47, 267-271 (2015).
36. Sales-Marques, C. et al. NOD2 and CCDC122-LACC1 genes are associated with leprosy susceptibility in Brazilians. Hum. Genet. 133, 1525-1532 (2014).
37. Wakil, S.M. et al. Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 67, 288-295 (2015).
38. Patel, N. et al. Study of Mendelian forms of Crohn's disease in Saudi Arabia reveals novel risk loci and alleles. Gut 63, 1831-1832 (2014).
39. Cader, M.Z. et al. C13orf31 (FAMIN) is a central regulator of immunometabolic function. Nat. Immunol. 17, 1046-1056 (2016).
40. Screpanti, I. et al. Lymphoproliferative disorder and imbalanced T-helper response in C/EBPβ-deficient mice. EMBO J. 14, 1932-1941 (1995).
41. Tanaka, T. et al. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell 80, 353-361 (1995).
42. Zierhut, M. et al. Immunology and functional genomics of Behçet's disease. Cell. Mol. Life Sci. 60, 1903-1922 (2003).
43. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 335, 1078-1080 (1990).
44. Mizushima, Y. Recent research into Behçet's disease in Japan. Int. J. Tissue React. 10, 59-65 (1988).
45. Price, A.L. et al. Long-range LD can confound genome scans in admixed populations. Am. J. Hum. Genet. 83, 132-135 author reply 135-139 (2008).
46. Purcell, S., Cherny, S.S. & Sham, P.C. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19, 149-150 (2003).
47. Jia, X. et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One 8, e64683 (2013).
48. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906-913 (2007).
49. Delaneau, O., Marchini, J. & Zagury, J.F. A linear complexity phasing method for thousands of genomes. Nat. Methods 9, 179-181 (2011).
50. Skol, A.D., Scott, L.J., Abecasis, G.R. & Boehnke, M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat. Genet. 38, 209-213 (2006).
51. Abecasis, G.R. et al. A map of human genome variation from population-scale sequencing. Nature 467, 1061-1073 (2010).
52. Ward, L.D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930-D934 (2012).
53. Adzhubei, I.A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010).
54. Yang, T.P. et al. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 26, 2474-2476 (2010).
55. Grundberg, E. et al. Mapping cis-and trans-regulatory effects across multiple tissues in twins. Nat. Genet. 44, 1084-1089 (2012).
56. Westra, H.J. et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet. 45, 1238-1243 (2013).
57. Baran, Y. et al. The landscape of genomic imprinting across diverse adult human tissues. Genome Res. 25, 927-936 (2015).
58. Dennis, G. Jr. et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4, 3 (2003).